Navigation Links
Researchers discover new culprit in atherosclerosis
Date:1/9/2012

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries. The research, published online by Nature Immunology on January 8, 2012, explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, accumulate in artery plaques.

"We have discovered that macrophages that accumulate in plaques secrete a molecule called netrin-1," said Kathryn J. Moore, PhD, senior author of the study and associate professor in the Departments of Medicine and Cell Biology at NYU Langone Medical Center. "Our study shows that netrin-1 blocks the normal migration of macrophages out of arteries, causing these immune cells to accumulate and promote the progression of atherosclerosis."

Artery plaques that break off causing vessel blockages, or potentially fatal heart attacks and strokes are known to have high macrophage cell content. Atherosclerosis is fueled by the presence of these cholesterol-laden macrophages in the artery wall. Typically, the immune system sends macrophages to clean up cholesterol deposits in arteries, but once they fill up with the unhealthy form of cholesterol they get stuck in the arteries, triggering the body's inflammatory response. The bloated macrophages then become major components of plaque lining artery walls. Until now, the mechanism by which macrophages become trapped has remained unknown.

In this new study, researchers show why macrophages remain in artery plaques leading to atherosclerosis. Netrin-1 promotes atherosclerosis by retaining macrophages in the artery wall. In fact, netrin-1 signals macrophages to stop migrating and as a result these cells accumulate within the plaque. In addition, study experiments show, genetically deleting netrin-1 can minimize atherosclerosis, reduce the level of macrophages in plaque and promote the migration of macrophages from plaques.

In the study researchers used a florescent tracking technique to label and monitor the movement of macrophage cells in and out of plaques. This experiment showed how macrophages were immobilized and retained in plaque by netrin-1 expression and also demonstrated macrophage emigration from plaque after the deletion of netrin-1.

"Our study identifies netrin-1 as a novel target for future therapeutic intervention for the treatment of atherosclerosis and cardiovascular disease," said Janine M. van Gils, PhD, lead author of the study and a post-doctoral researcher in the Marc and Ruti Bell Vascular Biology and Disease Program, Leon H. Charney Division of Cardiology, Department of Medicine at NYU Langone Medical Center. "This discovery provides new clues to help reduce the amount of plaque in arteries and the threat of atherosclerosis, a major cause of mortality in Western countries. The development of a new strategy to diminish macrophage accumulation in plaque offers great promise to reducing the occurrence of fatal cardiac events."


'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, ... residential and commercial clients in the northern Alabama and Georgia regions, is embarking ... Since 1977, Nobis Works has built a network of support and education facilities ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s ... unique opportunity to get hands-on experience in an emergency medical simulation, When Care ... to gain invaluable, real-life medical skills that are critical success in a future ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
(Date:12/7/2016)... PHILADELPHIA, PA (PRWEB) , ... December 07, 2016 ... ... story of a women growing up with a schizophrenic mother in a unique, ... social worker who specializes in treating trauma and addictive disorders at her private ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... YORK , December 8, 2016 ... focused on the research, distribution, and marketing of pharmaceutical ... affected by patent protection and expiration. Additionally, these firms ... Healthcare sector as a whole. Up for review this ... ), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP ), ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 ... STLT), a pharmaceutical company advancing technologies designed to ... the appointment of Chitra Edwin , Ph.D., ... and Compliance. Dr. Edwin will provide leadership for ... planning for regulatory approvals, preparation of regulatory submissions, ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial ... 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar ... Japan , Kenya , ... , China , Slovakia , ... & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology: